Redeye shares its view on Sleep Cycle ahead of the Q1 report, as the company’s evolution into a diversified sleep health platform gains momentum. While cyclical headwinds persist in the legacy consumer segment, the investment case is reinforced by over 150,000 early registrations for the upcoming sleep apnea screening feature—a clear validation of the MedTech strategy. Despite minor Q1 estimate revisions due to App Store softness, the early demand for the sleep apnea risk detection and continued strength in partnership revenues (+5% q/q) reinforce the shift toward high-margin, scalable growth engines.
LÄS MER
